Overview

* Cryoport ( CYRX ) Q3 revenue rises 15% yr/yr, driven by cell & gene therapy growth

* Company updates full-year 2025 revenue guidance to $170-$174 mln

* Cryoport ( CYRX ) reports Q3 net loss of $8.9 mln

* Company repurchased 483,397 shares for $3.7 mln in Q3

Outlook

* Cryoport ( CYRX ) raises full-year 2025 revenue guidance to $170 mln-$174 mln

* Company anticipates growth from DHL partnership and new supply chain centers

* Cryoport's ( CYRX ) 2025 guidance depends on economic and geopolitical factors

Result Drivers

* CELL & GENE THERAPY - Revenue from commercial cell & gene therapies grew 36% yr/yr, contributing significantly to Q3 results

* BIOSTORAGE/BIOSERVICES - Life Sciences Services revenue increased 16% yr/yr, with BioStorage/BioServices revenue up 21%, reflecting strong demand

* CRYOGENIC SYSTEMS - Life Sciences Products revenue grew 15% yr/yr, supported by sustained demand for cryogenic systems

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$8.90

Income mln

Q3 Gross 48.20%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the courier, postal, air freight & land-based logistics peer group is "buy"

* Wall Street's median 12-month price target for Cryoport Inc ( CYRX ) is $13.00, about 30.5% above its November 3 closing price of $9.04

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)